ArriVent BioPharma (AVBP) Reiterated at Overweight by Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on ArriVent BioPharma (NASDAQ: AVBP).The analyst commented, "ArriVent's (AVBP, OW) firmonertinib ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
